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THE development of resistance to 5-fluorouracil (FU) in Ehrlich ascites carcin-
oma (EAC) cells has been accompanied by decreases in the activities of uridine
kinase (Reichard et al., 1962) or of uridine phosphorylase and deoxyuridine phos-
phorylase (Reichard, Skold and Klein, 1959). These enzymes of the " uracil
pathway " of pyrimidine biosynthesis are involved in the conversion of FU to its
active metabolite, 5-fluorodeoxyuridine 5'-monophosphate (Chaudhuri, Montag
and Heidelberger, 1958; Harbers, Chaudhuri andHeidelberger, 1959; Skold, 1960a,
1960b). Significant decreases in uridine kinase activity were observed by Reichard
et al. (1962) in acetone powders of four sublines ofthe FU-sensitive tumour, ELD,
after treatment with FU for 25 to 30 passages, although the range of activity in
the acetone powders prepared from the parental (untreated) ELID cells was appar-
ently 40-70 units (Reichard et al., 1962; Skold, Magnusson and Revesz, 1962).
However, early resistance to FU occurred before significant decrease in uridine
kinase activity, and the authors concluded that other factors were responsible for
the development of such resistance.
Several years ago, studies similar in design to those of Reichard, Skold and
Klein (1959), were initiated in this laboratory on the relationship of uridine
kinase and uridine phosphorylase activities of Ehrlich ascites carcinoma cells to
the possible development of resistance to 6-azauracil (AzU) and 6-azauridine
(AzUR) in vivo. Since uridine phosphorylase (Pontis, Degerstedt and Reichard,
1961) and uridine kinase (Skold, 1960c) from EAC cells catalyse the formation of
AzUR from AzU, and the formation of 6-azauridine 5'-monophosphate (AzURP)
(the active metabolite (Pasternak and Handschumacher, 1959; Handschumacher,
1960)) from AzUR, decreased activity of one or both enzymes might be
associated with resistance to AzU. Handschumacher et al. (1962) stated that in
resistant bacteria and certain strains of experimental tumours (unidentified) a
common feature was the lack of formation of the 5'-phosphate from AzUR.
Thus, decreased phosphorylation of uridine and AzUR to the respective nucleo-
tides was associated with the development of resistance to AzUR in L-5178-Y
leukaemia cells (Pasternak et al., 1961). However, a mutant of Streptococcus
faecalis resistant to AzU was unable to convert AzU or uracil to the respective
nucleoside, but could phosphorylate uridine (Handschumacher, 1957). In
comparison, development ofresistance to AzUR during therapy ofhuman neoplas-
tic disease has been associated with an adaptive increase in the synthesis ofpyrimi-
dines via the de novo pathway (Fallon et al., 1962; Handschumacher et al., 1962).D. G. R. BLAIR AND A. D. HALL
During our experiments, it soon became apparent that there were large varia-
tions in the specific activities of uridine kinase and uridine phosphorylase of the
untreated EAC cells, as well as ofthe AzU- and AzUR-treated sublines, in succes-
sive transplant generations. No trends toward decreased or increased activity
were discernible. This communication reports the variations in the specific
activities of these enzymes which were observed in fresh cell-free extracts of the
cells during several transplant generations. Although decreased sensitivity to
AzU and AzUR could be demonstrated in the EAC sublines treated with AzU
and AzUR, respectively, no significant changes were observed in the specific
activities of the enzymes.
MATERIALS AND METHODS
Chemicals
Uridine-2-'4C (specific activity of 16 1 ,tCi/,mole; radio-chemically pure) was
obtained from New England Nuclear Corp., Boston, Mass. Uridine (A grade),
uridine 5'-monophosphate (UMP) (disodium salt; A grade) and 6-azauridine (A
grade; chromatographically homogeneous) were purchased from Calbiochem, Los
Angeles, California. Adenine, uracil, 6-azauracil (1,2,4-triazine-3,5-dione) and
the barium salt of D-3-phosphoglyceric acid were obtained from Nutritional
Biochemicals Corp., Cleveland, Ohio. A solution of the potassium salt of
D-3-phosphoglyceric acid was prepared by adding an equivalent amount of
K2S04 to an acidic solution ofthe barium salt to precipitate barium ions as BaSO4.
The supernatant solution obtained upon centrifugation was neutralized with
KOH.
Adenosine 5'-triphosphate (ATP) (disodium salt) was purchased from Sigma
Chemical Co., St. Louis, Mo., and bovine serum albumin (fraction V) was obtained
from The Armour Laboratories, Kankakee, Illinois. 5-Fluorouracil was a gift
from Hoffmann-La Roche Limited, Montreal, P.Q.
For injection into mice, azauracil and azauridine were dissolved in sterile
0.9% NaCl to form concentrations of 10 mg. per ml. Azauracil was dissolved,
just before use, by heating the suspension in hot water for several minutes.
Fluorouracil was dissolved in sterile 0.9% NaCl at a concentration of 10 mg.
per ml.
Mice
Male Swiss strain mice (Connaught), weighing between 18 and 26 g. each, were
obtained from the Animal Annex, University of Saskatchewan, Saskatoon, or
from the Connaught Medical Research Laboratories, University of Toronto,
Toronto, Ontario. The mice were housed in groups of 5 or 6 per cage, and were
fed mouse and rat pellets and water ad libitum.
Tumour
The parental (sensitive) Ehrlich ascites carcinoma (EAC/s) which was used
was a hypotetraploid line having a modal chromosome number of 74 (H. D. Kirk,
S. B. Hrushovetz and E. Harder, personal communication). This tumour was
obtained in 1961 from Dr. A. R. P. Paterson, McEachern Laboratory, University
ofAlberta, Edmonton, Alberta, who obtained it from Dr. C. C. Stock ofthe Sloan-
Kettering Institute, New York, N.Y. It has been maintained by the weekly
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serial, intraperitoneal transfer of approximately 6 x 106 cells (haemocytometer
count) in 0-9% NaCl in male Swiss mice. Two AzU-treated sublines (EAC/AzU1
and EAC/AzU2) were derived from cells of the 13th transfer generation of the
EAC/s tumour, taken from one mouse, and maintained by the weekly, serial,
intraperitoneal transfer of 6 x 106 cells. Mice bearing subline EAC/AzU1 were
treated originally with a dose of AzU equal to 250 mg./kg. body weight/day for
6 days, beginning 24 hours after the inoculation of cells. This dose was increased
to 750 mg./kg. body weight/day at the 4th cell transplant generation. Mice bear-
ing subline EAC/AzU2 were treated similarly to those bearing subline EAC/AzU1,
except that the dose of AzU was 500 mg./kg. body weight/day for 6 days. This
subline was discontinued after 17 generations. Similarly, an AzUR-treated
subline (EAC/AzUR) was derived from the 46th transfer generation of the EAC/s
tumour and maintained by the weekly serial, intraperitoneal transfer of 6 x 106
cells. Mice bearing this subline were treated originally with a dose of AzUR
equal to 150 mg./kg. body weight/day for 6 days beginning 24 hours after the
inoculation of cells. This dose was increased to 300 mg./kg./day at the 4th cell
transplant generation.
Tests of resistance to drugs
Mean host survival time.-The mean survival time oftumour-bearing hosts was
determined periodically for groups of AzU- or AzUR-treated mice and for control
groups inoculated with the same number of cells (usually 6 X 106) and treated
with a volume of0 9% NaCl equal to that in which the AzU orAzUR wasdissolved.
Each group consisted of at least 4 animals. The therapeutic index (T.I.) was
calculated by dividing the difference between the mean survival times (days) of
the drug-treated and control groups by the mean survival time for the control
group. The T.I. was determined for each cell transplant generation of the
EAC/AzU1, EAC/AzU2 and EAC/AzUR sublines.
Mean total packed cell volume.-The EAC/s and EAC/AzU1 cell lines were
each tested directly for growth inhibition by AzU or AzUR in vivo. Mice were
divided into two groups composed of equal numbers of the same mean weight
and weight range. Mice of both groups were each inoculated intraperitoneally
with 6 x 106 cells (haemocytometer count) of the cell line being tested. One
group of mice was treated, as described above, with the particular drug being
tested, while the other (control) group was treated with a volume of 0.9% NaCl
equivalent to that injected with the drug. At 7 days after cell inoculation,
the total packed cell volume (TPCV) of free cells in the peritoneal cavity of each
animal was determined essentially as described by Paterson (1960), and the mean
TPCV for the drug-treated group was compared with that for the control group.
The data for the EAC/AzU1 subline were compared with similar data for EAC/s
cells.
Preparation and analysti of cell extractsfor enzyme assays
Tumour cells for the preparation of cell-free extracts for enzyme assays were
usually obtained from animals 8 or 9 days after cell inoculation. During initial
stages ofthe studies on EAC/s, EAC/AzUi and EAC/AzU2 cells, cells from a repre-
sentative tumour of the group, or tumour cells pooled from several mice of the
group, were used to prepare the cell-free extract, but this method was later
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abandoned in favour of preparing individual extracts from at least three tumours
from each group of animals.
The cells and ascitic fluid from a mouse were drained into an ice-cooled centri-
fuge tube, and the cells were sedimented by centrifugation at 2000 r.p.m. for
10 minutes in a model CM International centrifuge. The packed cells were
washed twice with cold 0-9 /o NaC1, resedimented each time by centrifugation,
and suspended into two volumes of 0-9 /0 NaCl. The cell suspension was then
subjected to ultrasound in a 10 Kc. Raytheon ultrasonic unit at 0-4° C. until all
the cells were broken (as determined microscopically), and then centrifuged for
1 hour at 105,000 x g in a Spinco, model L, centrifuge. The resultant super-
natant fluid was used immediately for the assay of uridine kinase and uridine
phosphorylase activity. Freshly prepared cell extracts were always used to
avoid loss of enzyme activity. Storage of the extracts at -20° C. for 75 days
resulted in the loss of 9000 ofthese activities, and the activities were also lost upon
lyophilization of the extracts (D. J. Rainnie and D. G. R. Blair, unpublished
observations).
The protein content of the cell-free extract was determined by the method of
Lowry et al. (1951) with the use ofbovine serum albumin (fraction V) as a standard.
The haemoglobin content was estimated by the cyanomethaemoglobin method of
Evelyn and Malloy (1938) and was subtracted from the total protein content for
the purpose of calculating enzyme specific activities. Cells from grossly bloody
ascites tumours were not used.
Assay of enzyme activities
Uridine kinase and uridine phosphorylase activities of the cell-free extracts of
the tumour cells were estimated simultaneously by a radioisotopic method similar
to that employed by Skold (1960d) for the measurement of these activities in
acetone powder extracts of EAC cells.
The enzyme reaction medium (0.3 ml.) contained MgCl2 (40 mM); tris(hydroxy-
methyl)aminomethane (Tris) buffer, pH 7-4 (33 mm); phosphate buffer, pH 7.4
(25.5 mM); ATP (13.3 mM); potassium D-3-phosphoglycerate (24.7 mM); uridine-
2-14C (26.7 mair, 0 032 ,uCi) and the cell extract. Incubations were carried out at
37-38° C. for 15 minutes, and enzymatic activity was terminated by the addition
of 0 03 ml. of ice-cold 4 M perchloric acid. The supernatant solution, obtained by
centrifugation, was heated in boiling water for 1 hour to break pyrophosphate
and purine-glycosyl bonds. Perchlorate ions were precipitated from the cooled
solution as KC104, by neutralization with cold 4 M KOH, and sedimented by
centrifugation.
A 0 05 ml. aliquot of the supernatant solution, obtained by centrifugation,
was applied to a strip of Whatman No. 1 filter paper (2 cm. or 1 inch wide) and
subjected to descending chromatography in absolute ethanol-saturated Na2B407
5 M ammonium acetate 0 5 M versene (360: 160: 40: 1, v/v) (Reichard and
Skod, 1958). Standards of uracil, uridine, UMP and adenine were chromato-
graphed at the same time. The ultraviolet (u.v.) light-absorbing substances were
located on the developed chromatograms with a " Chromatolite " u.v. lamp, and
areas corresponding to uracil, uridine and UMP on standard chromatograms were
cut out and immersed in 3 0 ml. of distilled H20 for at least 24 hours. Aliquots
(0.25 ml.) of the eluate were spread on aluminium planchets and dried in air at
room temperature, and the radioactivity was determined in a Nuclear-Chicago
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gas-flow system as described by Blair and Hall (1965). The percentages of total
radioactivity in uracil, uridine and UMP were calculated for each sample, and the
amounts of uracil and UMP formed from uridine-2-14C were calculated from these
values and the specific activity of uridine-2-14C.
Because the enzymatic formation ofuracil and UMP is not perfectly linear with
enzyme concentration (Skold, 1960d), the assay for each cell extract was done with
several enzyme concentrations to ensure the rectilinear portion of the activity
curve. Fig. 1 shows the formation of uracil and UMP (15 minutes) versus the
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FIG. l -Dependence of uridine kinase (0 0s) and uridine phosphorylase ( ----0)
activities on the amount of EAC/s coll extract. The reaction time was 15 minutes.
amount of EAC/s cell extract in a representative experiment. Enzyme activities
were calculated from the initial slopes of the activity curves (Fig. 1) as ,umoles
of uracil or UMP formed per mg. of protein (corrected for haemoglobin) per hour.
Fig. 2 shows that the formation of UMP was linear with time for 15 minutes,
under the conditions described above, while uracil formation was linear for about
30 minutes.
The concentrations of MgCl2 and potassium 3-phosphoglycerate which were
used in the enzyme reaction medium were identical to those employed by Skold
(1960d), whereas the concentrations of ATP, Tris, phosphate and uridine-2-14C
were, respectively, 1-65, 1'15, 1P55 and 15-3 times as large as those used by Skold
(1960d). Fig. 3 and 4 show that the concentrations of phosphate and uridine,
respectively, which were used in the present experiments were optimal. Aden-
osine 5'-triphosphate was retained throughout the enzymatic reaction, and its
concentration, measured by a combined spectrophotometric and anion-exchange
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FIG. 2. Uridine kinase (0 0) and uridine phosphorylase ( -0---) activities of a
EAC/scell extract as a function of reaction time. The volume of cell extract was 0-04ml.
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FrG. 3.-Dependence of the uridine kinase (0 0) and uridine phosphorylase (0 - -0)
activities of a EAC/s cell extract on phosphate concentration. The volume of cell extract
was 004 ml., and the reaction time was 15 minutes.
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resin chromatographic method (Blair, Stone and Potter, 1960), at the end (15
minutes; 0-06 ml. of EAC/s cell extract) was 7 18 mm. When the initial ATP
concentration was 8-0 mm rather than 13-3 mM, UMP formation was 98%, and
uracil formation 124%, of the formation at the higher concentration.
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FIG. 4.-Dependence of the uridine kinase (0 * 0) and uridine phosphorylase (*- - - -*)
activities of a EAC/s cell extract on uridine concentration. The volume of cell extract was
0 04 ml., and the reaction time was 15 minutes.
RESULTS
Specific activities of uridine kinase and uridine phosphorylase in extracts of EAC/s
cells
The specific activities of uridine kinase and uridine phosphorylase in extracts
of EAC/s cells varied appreciably, and apparently randomly, over the span of
35 cell transplant generations studied (Fig. 5). The mean uridine phosphorylase
specific activity varied from a high of 1.413 ,umoles/hr/mg. protein at celltransplant
generation No. 16 to a low of 0-520 ,umole/hr/mg. protein at generation No. 33.
The range ofvalues for individual samples was 0-348-1-413 ,umoles/hr/mg. protein.
The mean uridine kinase specific activity of the same cell extracts varied
from 2-610 ,tmoles/hr/mg. protein at cell transplant generation No. 24 to 0-960
,/mole/ hr/mg. protein at generation No. 12. The range of values for individual
samples was 0 960-2-880 ,umoles/hr/mg. protein.
Cells of transplant generations 12-14 were obtained from 10-day-old tumours,
whereas cells of generations 16, 24, 33, 36 and 46 came from 8-day-old tumours,
and cells of the other generations were from 9-day-old tumours. Close examina-
tion of Fig. 5 shows that there is no obvious correlation between the activities and
71
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the age of the tumour: The highest and lowest activities of uridine phosphorylase
were obtained for extracts from 8-day-old tumours, and, although the highest
uridine kinase activity was obtained for an extract of cells from an 8-day-old
tumour, the third-lowest activity was also obtained for cells from a tumour of the
same age. However, the average mean specific activities (,umoles/hr/mg. protein
± standard deviation) of uridine kinase for 8, 9 and 10-day-old tumour cells were
1-932 ± 0-554, 19481 ± 0-416 and 19632 ± 0-536, respectively, and the correspond-
ing average mean specific activities for uridine phosphorylase were 0-946 + 0-334,
0-831 ± 0*233 and 0-715 ± 0-157, respectively. There was no significant differ-
ence between the three values in each group.
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FIG. 5. Specific activities ofuridine kirase (0 * 0) and uridine phosphorylase (0 0)
in extracts of EAC/s cells at successive transplant generations. The vertical lines indicate
ranges ofvalues.
Growth of the EAC/s tumour in male Swiss mice was similar to that described
by Klein and Revesz (1953) for the Ehrlich ascites carcinoma, with no definite
exponential phase, and the terminal phase began at about 9 days after cell inocula-
tion (6.2 x 106 cells) (Rainnie, 1967; Rainnie and Blair, 1969). The viability of
free cells, collected from the peritoneal cavities of 10 tumour-bearing mice each
day during the determination of the growth curve, was estimated by a dye-exclu-
sion method (Phillips and Terryberry, 1957) with erythrosin B. The viability of
cells ranged from 71-8 to 92.7% during the entire growth period, and was 83 1,
87-1 and 89.4% for cells from 8-, 9- and 10-day-old tumours, respectively (Rainnie,
1967). Cell-size distribution studies (Coulter cell counter and plotter) on the
same cell populations did not indicate any change in the constituent populations
between days 3 and 12 oftumour growth (Rainnie, 1967; Rainnie and Blair, 1969).
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Specific activities of uridine kinase and uridine phosphorylase in extracts of
EAC/AzU1 and EAC/AzU2 cells
The specific activities of uridine kinase and uridine phosphorylase in extracts
ofEAC/AzU1 and EAC/AzU2 cells from 8- or 9-day-old tumours also varied consid-
erably over the 33 and 17 cell transplant generations, respectively, which were
investigated (Fig. 6). No trend could be observed toward decreased or increased
uridine phosphorylase specific activities with 6-azauracil treatment. The mean
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FiIG. 6. Specific activities of uridine kinase (0) and uridine phosphorylase (0) in extracts
of EAC/AzU, ( ) and EAC/AzU, ( ----) cells at successive transplant generations.
The vertical bars indicate the range of valuies.
specific activity ofthe enzyme fromEAC/AzUj cells variedfrom 0 304,amole/hr/mg.
protein at cell transplant generation No. 15 to 0-958 ,umole/hr/mg. protein at
generation No. 12, while that from EAC/AzU2 cells varied from 0396 ,umole/hr/mg.
protein at transplant generation No. 17 to 1-125 ,umoles/hr/mg. protein at
generation No. 12. Remarkable similarity is seen in the specific activities, and
in the variation, from transplant generation to transplant generation, in the
activities of the enzyme from the two cell sublines. This result suggests (a) that
cells of the two sublines are biochemically similar and (b) that the enzymes from
both types of cells react similarly to factors involved in assaying the enzyme
activity.
The specific activity of uridine kinase from EAC/AzUj cells appeared first of
all to increase, and, later, to decrease with AzU treatment. A similar rise was
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observed for the EAC/AzU2 subline, but this subline was discontinued before any
subsequent decrease was observed. The mean specific activity ofuridine kinase
from EAC/AzU, cells varied from 1210 ,umoles/hr/mg. protein at cell transplant
generation No. 33 to 2-740 ,tmoles/hr/mg. protein at generation No. 8, while
the specific activity of the enzyme from EAC/AzU2 cells varied from 1-910
,tmoles/hr/mg. protein at generation No. 15 to 3-290 /tmoles/hr/mg. protein at
generation No. 17, when the subline of cells was discontinued. No continuous
trend was observed toward increased or decreased enzyme activity with
6-azauracil treatment.
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FIG. 7.-Specific activities ofuridine kinase ( 0) and uridine phosphorylase (0- - - -0)
in extracts of EAC/AzUR cells at successive transplant generations. The vertical bars
indicate the range of valuies.
Specific activities of uridine kinase and uridine phosphorylase in extracts of
EAC/AzUURcells
The specific activities of the two " uracil pathway " enzymes in extracts of
EAC/AzUR cells also varied considerably over 11 cell transplant generations from
the commencement of treatment with 6-azauridine, without any definite trend
toward increased or decreased activities (Fig. 7). In this case the enzyme specific
activities were determined at each successive transplant generation, wherepossible,
in order to ascertain the changes from one generation to the next.
The mean specific activity of uridine phosphorylase varied from 0540 ,umole/
hr/mg. protein at transplant generation No. 9 to 1-625 Fumoles/hr/mg. protein at
generation No. 6, while the mean specific activity of uridine kinase varied from
0626 ,tmole/hr/mg. protein at generation No. 2 to 1'740 ,umoles/hr/mg. protein
atgenerationNo. 7.
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With theexception ofcells ofgeneration No. 9, whichwereobtained from 8-day-
old tumours, EAC/AzUR cells were harvested from 9-day-old tumours.
Development of resistance ofEAC/AzU, and EAC/AzU2 cells to 6-azauracil and of
EAC/AzUR to 6-azauridine
Although the Ehrlich ascites carcinoma is only mildly sensitive to inhibition
by 6-azauracil (gorm and Keilova', 1958), decreased sensitivity to the drug could
be demonstrated, by host survival time, for both the EAC/AzU1 (Table I) and the
TABLE I.-Development of Resistance to 6-azauracil in the EAC/AzU1
Subline of the Ehrlich Ascites Carcinoma (EAC/s)
Dose of No. of Mean survival time
Cell 6-azauracil mice in days ± S.D.
transplant (mg./kg./day , ,
generation for 6 days) T* C* T* C* T.I.t
1 . 250 . 5 5 . 15-8+1-72 15-6±1*96 04013
2 . . 6 6 . 15-0+0-58 15-74094 . -0 045
3 . . 5 6 . 16 6±3 20 15-5±2*69 . 04071
4 750 . 6 6 . 20*0+2-08 16-7±1*38 0-198
7 . . 6 6 . 17-0±2-00 15-0±0-58 0 133
10 . . 5 6 . 19-4±2-58 18*5±3 30 04049
12 . . 5 5 . 17-6±1.20 16-4±1-50 0 073
13 . . 6 5 . 16*2±093 16*2±0-75 0
14 . . 6 6 . 17*7±2-06 18-8±2-91 -0 062
16 . . 5 5 . 15-6±b174 17-8±1-72 -0-124
18 . . 5 5 . 15-4±1-96 17*2±2*48 -0104
24 . . 5 4 . 18-4±1-20 18-3±0-83 . 0
27 . . 6 5 . 17-0+1-41 18*0±1*10 . -04055
29 . . 6 6 . 13-8±1-86 14-5±1-39 . -0-048
33 . . 4 5 . 21-0±4-64 21*4±4 27 . -04019
* T, treated; C, control.
t T-I., therapeutic index.
EAC/AzU2 (Table II) sublines after about 12 transplant generations under treat-
ment with AzU. The parent EAC/s cells (transplant generation No. 1 in Tables
I and II) were not very sensitive to an AzU dose of 250 mg./kg./day (Table I)
but were sensitive to a doubled dose (Table II). The effect of changing the dose
of AzU from 250 to 750 mg./kg./day for EAC/AzU, cells at transplant generation
No. 4 was an increase in the therapeutic index which later decreased to zero at
generation No. 13.
Decreased sensitivity of EAC/AzUR cells to 6-azauridine was apparent after
12 cell transplant generations under treatment with 150 mg. of AzUR/kg./day
forthree generations andwith 300 mg. ofAzUR/kg./dayforninegenerations (Table
III). Change ofthe dosage from 150 to 300 mg./kg./day produced an appreciable
increase in the therapeutic index which decreased in succeeding generations.
In Table IV the mean survival times of mice inoculated with EAC/s or EAC/
AzU, cells and treated with AzU, AzUR or FU are presented. The therapeutic
index for a dose of 750 mg. of AzU/kg./day against the EAC/s tumour was 0-163
to 0*339, whereas it was 0*032 against the 32nd transplant generation of the
EAC/AzU1 tumour. Comparison of the T.I. for 150 mg. of AzUR/kg./day
against the EAC/s tumour with that against theEAC/AzUj tumour shows that the
latter was cross-resistant to this dose of azauridine. On the other hand, the
EAC/AzU1 tumour was more sensitive than the parental EAC/s tumour to FU.
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TABLE II.-Development of Resistance to 6-azauracil in the EAC/AzU2
Subline of the Ehrlich Ascites Carcinoma (EAC/s)
No. of
Cell mice
transplant
generation T* C*
1
3
4
8
10
11
12
13
14
15
16
17
5
5
6
5
4
6
5
6
6
5
5
4
6
6
6
6
6
6
6
6
6
6
6
6
Mean survival time
in days ± S.D.
T*
17*2±2*49
19* 6±2 42
17*0±1 53
18-0±1 67
19*5±1 12
15- 7±1 11
15.4±2-06
16-8±1 46
18*8±0-68
18-8±5- 76
17 0±1-79
16*3±1 15
C*
15*8±4-26
15*7±2-21
13 7+1 70
15-2±1 -57
17-0±3-51
15*7±1 -27
17-0+0*82
17 3±0*94
19*2±0 69
16-5±4 42
18 8±1*46
14*7±1-25
* T, treated; C, control. Treated animals received 500 mg.
6-azauracil/kg./day for 6 days.
tT.I., therapeutic index.
TABLE III.-Development of Resistance to 6-azauridine in the EAC/AzUR
Subline of the Ehrlich Ascites Carcinoma (EAC/s)
Dose of No. of
6-azauridine mice
(mg-/kg./clay v
for 6days) T* C*
150 . 6 6.
. 6 5
6 6.
300 . 6 5.
. 4 6
. 4 6
. 4 6
. 5 6
6 6.
Mean survival time
in days + S.D.
T* C*
19-2±5-13 15-0+1-53
21-5±5-99 14-8±5-04
18-2±2-97 13-6±1-60
18-3±4*42 9-8+0-98
11-0±1-23 11*2±1-77
16*0±2-24 12-0+1-15
14-5+0*38 17-2+2 14
16*0±3-29 13-2+1-46
17*0+3 17 17-5+1-98
* T, treated; C, control.
t T.I., therapeutic index.
TABLE IV.-Effect of 6-azauracil, 6-azauridine and 5-fluorouracil Treatment on
the Survival of Mice Inoculated with EAC/s or EAC/AzU1 Ehrlich Ascites
Carcinoma Cells
Cell
transplant
Cells generation
EAC/s . 29
44
46
60
EAC/AzU,. 32
34
48
Drug
AzU
AzU
AzUR
FU
AzU
AzUR
FU
Dose
(mg./kg.c/day
for 6 days)
750
750
150
25
750
150
25
No. of
mice
T* C*
6 6
6 6
6 6
6 6
6 6
6 6
6 6
Mean survival time
in days + S.D.
T* C*
19-0±2-31
25-7+6±-10
19-2±5 13
25-5+4- 99
18*2±3-45
16- 7±4-42
>49 8$
16-3±3-20
19-2±3-02
15.0±1 53
19* 5+3 20
17-7 7±506
17*5+2-06
16-8+0-90
T.I.t
0-163
0*339
0 280
0-308
0-028
.-0-046
. > 1P964
* T, treated; C, control.
t T.I., therapeutic index.
t One mouse alive after 132 days without any gross sign of tumour growth.
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T.I.t
0 202
0 249
0.241
0*184
0*147
0
-0 094
0-029
-0-018
0-139
-0 097
0-108
Cell
transplant
generation
1
2
3
4
7
8
9
10
12
T.I.t
0 280
0X452
0 338
0-870
-0-018
0 330
-0-157
0*212
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Table V presents the mean total packed cell volume data for the experiments
with 6-azauracil and 6-azauridine presented in Table IV, and for some additional
experiments with EAC/s cells with 6-azauracil and 6-azauridine. It is readily
apparent that corresponding doses of AzU or AzUR inhibited the growth of
EAC/s cells more effectively than that of EAC/AzU1 cells. Thus, these data
support the survival data in showing that the EAC/AzU1 cells are less sensitive
to AzU and AzUR than are EAC/s cells.
TABLE VT.-Effect of 6-azauracil and 6-azauridine on the Total Packed Cell Volume
of EAC/s and EAC/AzU, Ehrlich Ascites Tumours
No. of Meain TPCV
Cell Dose mice (ml. + S.D.)
transplant (mg/kg/da
Cells generation Drug for 6 davs) T* C* T* C* T/C
EAC/s 44 AzU 750 6 6 0 77±0 58 2 - 14±0 * 39 0*36
136 AzU 750 8 10 0-25±023 1-05±0-37 0-24
46 AzUR 150 6 6 0* 54±0 02 1 85+0 08 0*29
134 AzUR 300 7 9 0* 29±0 * 21 1*23±0 87 0*24
EAC/AzU,. 32 AzU 750 5 5 1 91±0 20 2 * 58±0* 23 0*74
34 AzUR 150 4 6 1*01±0226 1 58±0 09 0*64
* T, treated; C, control.
Comparison of the enzyme specific activities (Fig. 6) of the EAC/AzU1 subline
with the azauracil-sensitivity data (Tables I, IV and V) shows that there was no
correlation between uridine kinase and uridine phosphorylase activity of the cell
extracts and sensitivity to azauracil. Similarly, there was no apparent correlation
between the enzyme specific activities of the EAC/AzU2 cells (Fig. 6) and sen-
sitivity to azauracil (Table II), or between the enzyme specific activities of the
EAC/AzUR cells (Fig. 7) and sensitivity to azauridine (Table III).
DISCUSSION
In the experiments described in this report, alterations in the specific activities
of uridine kinase or of uridine phosphorylase, which are activating enzymes for
azauracil (Pontis, Degerstedt and Reichard, 1961; Skold, 1960c), could not be
correlated with the development of resistance to 6-azauracil and 6-azauridine in
AzU- and AzUR-treated sublines of the Ehrlich ascites carcinoma. This result
is similar to that obtained by Reichard et al. (1962) in regard to the development
of resistance of Ehrlich ascites carcinoma cells to 5-fluorouracil. In that case two
tumour lines became resistant to FU before a decrease in either uridine kinase or
uridine phosphorylase occurred, and it appeared that other factors were respon-
sible for the development of the resistant state.
One mechanism of resistance to 6-azauridine, which has been definitely estab-
lished for L-5178-Y cells cultured in vitro, is decreased uridine kinase activity
(Pasternak et al., 1961). Our results suggest that this mechanism was not involved
in the development of resistance to AzU in EAC/AzU1 and EAC/AzU2 cells,
although EAC/AzU, cells were cross-resistant to AzUR, and in the development
of resistance to AzUR in EAC/AzUR cells. The lack of cross-resistance of
EAC/AzU, cells to FU supports this conclusion. Another mechanism (or mechan-
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isms), such as decreased cellular permeability to the drugs, decreased sensitivity
oforotidylate decarboxylase to inhibitionby azauridylic acid or increased synthesis
of pyrimidines de novo (Fallon et al., 1962), appears to be operative. The work
ofPinsky and Krooth (1967a, 1967b) on the growth of human diploid cell strains
in thepresence ofAzUR suggests that resistance to AzU and AzUR could involve
an increase in thespecific activity ofthetargetenzyme, orotidylate decarboxylase,
in response to an accumulation of a precursor of UMP.
The decrease in sensitivity to AzU and AzUR which developed in the sublines
of the EAC/s tumour was not great, however, and may not have been extensive
enough for any significant alterations in the specific activities of uridine kinase
and uridine phosphorylase to be detected. The variability of these activities in
different transplant generations ofthe parent EAC/s cells, makes it clear that only
relatively large changes would be significant. The specific activity of uridine
phosphorylase in extracts from individual 8- to 10-day-old EAC/s tumours
varied from 0-348 to 1-413 ,umoles/hr/mg. protein over the span of 35 cell genera-
tions, while that of uridine kinase varied from 0-962 to 2-880 ,umoles/hr/mg.
protein, the highest values being 4-1 and 3 0 times the lowest, respectively. In
comparison, a similarrange ofvalues (50-140 ,tmoles ofUMP or uracil/15 minutes/
mg. acetone powder) was reported by Skold (1960d) for activities of these two
enzymes in acetone powders prepared from EAC cells from tumours of unstated
age and inoculum size. The -range of values found by Reichard et al. (1962) and
Skold et al. (1962) for uridine kinase activity in acetone powders of ELD Ehrlich
ascites cells was 40-70 units.
It waspointed out in the "Results" section that the mean activities of either
uridine kinase or uridine phosphorylase in extracts from 8-, 9- or 10-day-old
tumours were not significantly different with respect to tumour age. Recent
experiments (Rainnie and Blair, 1969), in which the specific activities of the two
enzymes were measured in separate assays concurrently with the progression of
growth of the Ehrlich ascites carcinoma from an inoculum of 5-2 x 106 cells,
indicated that the specific activity of uridine phosphorylase was significantly
greater in extracts of cells from 10-day-old tumours than in extracts of cells from
8- or 9-day-old tumours. The results reported in this communication differ from
those cited above (Rainnie and Blair, 1969), but a direct comparison of the two
sets of data is not valid because of (1) the different assay methods and (2) the use
of cells from different cell transplant generations, which may have been initiated
with different cell doses, thus perhaps shifting the growth curve, in the one case,
and of cells from only one celltransplant generation in the other.
Reichard et al. (1962) considered the irregular variations which they observed
in the activities of uridine phosphorylase, uridine kinase and deoxyuridine phos-
phorylase in acetone powders from four FU-resistant EAC cell lines to be random
and probably caused by the inhomogeneity of the animals which were used.
Physiological variation was undoubtedly a factor in those experiments, as well
as in those described in this report. Numerous other factors must be involved,
however, and it is notpossible at this time to state what portion of the total effect
is contributed by physiological variation. It is apparent that the use of freshly
prepared cell extracts or of acetone powders provides essentially the same degree
of variation in enzyme specific activities.
Demonstration of resistance to drug therapy is difficult when the drug is not
highly effective against the disease state, as in the case oftreatment of the Ehrlich
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ascites carcinoma with 6-azauracil or 6-azauridine. Simultaneous metabolic
changes may be small in such cases, and demonstration of them is more difficult
when the range of " normal " values is relatively large, as for uridine kinase and
uridine phosphorylase in EAC cells. Small, but nevertheless important, altera-
tions may be completely obscured.
SUMMARY
The specific activities of uridine phosphorylase and uridine kinase were
determined in freshly prepared cell-free extracts of Ehrlich ascites carcinoma cells
and ofcells from two 6-azauracil-treated sublines andfrom one 6-azauridine-treated
subline over several cell transplant generations for each cell line. All the drug-
treated sublines had become less sensitive (more resistant) to the drug with which
they were treated after 12 transplant generations under treatment. However,
no definite trend toward decreased or increased activities of uridine kinase or
uridine phosphorylase could be correlated with the development of resistance.
It was found that the specific activities of the two enzymes in all cell lines varied
greatly in successive cell transplant generations. This variation may have
obscured any changes in the enzyme activities which may have accompanied the
development of resistance to 6-azauracil and 6-azauridine. Cells resistant to
6-azauracil were cross-resistant to 6-azauridine but not to 5-fluorouracil.
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